ロード中...
Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
Neoadjuvant chemotherapy plus trastuzumab (NCT) increases the rate of pathological complete response (pCR) and event-free survival (EFS) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC). pCR in this setting is associated with improved EFS. Whether NCT pr...
保存先:
出版年: | Oncotarget |
---|---|
主要な著者: | , , , , , , , , , , , , , , , , |
フォーマット: | Artigo |
言語: | Inglês |
出版事項: |
Impact Journals LLC
2015
|
主題: | |
オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4914352/ https://ncbi.nlm.nih.gov/pubmed/26334099 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.4801 |
タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|